Business
Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion
Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams."
About this update from Hanmi Pharmaceutical Co., Ltd.
[{"type":"text","content":"Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes'","length":124,"tagName":"p"},{"type":"text","content":"Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America","length":89,"tagName":"p"},{"type":"text","content":"Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico","length":80,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, April 2, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams."","length":300,"tagName":"p"},{"type":"image","alt":"Aditams","displaySize":"","headline":null,"caption":"Aditams","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/826c3b91b6239c3c959b4b16c7f11c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CPio0FNDGcq4WeHTAhTGQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/826c3b91b6239c3c959b4b16c7f11c55","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2653570/Aditams_Photo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hanmi Pharmaceutical announced that it has completed the launch of Aditams in Mexico under the export agreement signed in October 2020 with the Mexican pharmaceutical company 'Laboratorios Silanes'. Under the agreement, Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025.","length":351,"tagName":"p"},{"type":"text","content":"Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). It is also noteworthy as the first prescription drug in Korea to apply Poly-Cap technology, which integrates multiple active ingredients into a single capsule.","length":416,"tagName":"p"},{"type":"text","content":"Laboratorios Silanes, a leading pharmaceutical company in Mexico founded in 1943, i...